Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study

  FDC of arterolane maleate + piperaquine phosphate (n = 141)
Sex, n (%)  
 Male 73 (52 %)
 Female 68 (48 %)
Age (6 months to ≤12 years), n 141
 Median 5.11
 Mean ± SD (min, max) 5.9 ± 3.45 (0.06, 12.11)
Age group 1 (6 months to <2 years), n 22
 Median 1.05
 Mean ± SD (min, max) 0.9 ± 0.39 (0.06, 1.11)
Age group 2 (2 to <6 years), n 49
 Median 4.00
 Mean ± SD (min, max) 3.8 ± 1.07 (2.00, 5.11)
Age group 3 (6 to ≤12 years), n 70
 Median 9.00
 Mean ± SD (min, max) 8.8 ± 1.83 (6.00,12.11)
Race, n (%)  
 African 123 (87 %)
 Asian 18 (13 %)
Height (cm)  
 Median 106.00
 Mean ± SD (min, max) 105.7 ± 19.24 (58.00,146.00)
Weight (kg)  
 Median 17.00
 Mean ± SD (min, max) 18.5 ± 6.84 (7.00, 36.00)
Baseline axillary temperature (°C)  
 Median 38.20
 Mean ± SD (min, max) 38.4 ± 0.88 (36.50, 40.50)
No. of baseline P. falciparum asexual parasites (µL−1)  
 Median 44,720.00
 Mean ± SD (min, max) 45,428.6 ± 31,481.95 (1040.00, 99,860.00)
  1. SD standard deviation, Min minimum, Max maximum